Your browser doesn't support javascript.
loading
Implementation of subjective cognitive decline criteria in research studies.
Molinuevo, José L; Rabin, Laura A; Amariglio, Rebecca; Buckley, Rachel; Dubois, Bruno; Ellis, Kathryn A; Ewers, Michael; Hampel, Harald; Klöppel, Stefan; Rami, Lorena; Reisberg, Barry; Saykin, Andrew J; Sikkes, Sietske; Smart, Colette M; Snitz, Beth E; Sperling, Reisa; van der Flier, Wiesje M; Wagner, Michael; Jessen, Frank.
Afiliação
  • Molinuevo JL; Alzheimer's Disease and Other Cognitive Disorders Unit, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Barcelona ßeta Brain Research Center, Pasqual Maragall Foundation, Barcelona, Spain. Electronic address: jlmoli@clinic.cat.
  • Rabin LA; Department of Psychology, Brooklyn College and The Graduate Center of CUNY, Brooklyn, NY, USA; Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA.
  • Amariglio R; Center for Alzheimer Research and Treatment, Brigham and Women's Hosptial and Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Buckley R; Center for Alzheimer Research and Treatment, Brigham and Women's Hosptial and Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Florey Institute of Neuroscience and Mental Health, Melbourne, Australia; Melbourne School of Psychological Sciences, University of Melbourne, Melbou
  • Dubois B; Institute of Memory and Alzheimer's Disease and Brain and Spine Institute (ICM) Pitié Salpetriere University Hospital, Sorbonne Universities, Pierre et Marie Curie University, Paris, France.
  • Ellis KA; Department of Psychiatry, Royal Melbourne Hospital, The University of Melbourne, Melbourne, Australia.
  • Ewers M; Institute for Stroke and Dementia Research, Klinikum der Universität München Ludwig-Maximilians-Universität LMU, Munich, Germany.
  • Hampel H; Institute of Memory and Alzheimer's Disease and Brain and Spine Institute (ICM) Pitié Salpetriere University Hospital, Sorbonne Universities, Pierre et Marie Curie University, Paris, France; AXA Research Fund & UPMC Chair, Paris, France.
  • Klöppel S; Department of Psychiatry and Psychotherapy, University Medical Center Freiburg, Freiburg, Germany; Center of Geriatrics and Gerontology, University Medical Center Freiburg, Freiburg, Germany.
  • Rami L; Alzheimer's Disease and Other Cognitive Disorders Unit, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Reisberg B; Department of Psychiatry, New York University Langone Medical Center, New York, NY, USA.
  • Saykin AJ; Indiana Alzheimer Disease Center, Indiana University School of Medicine, Indianapolis, IN, USA; Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN, USA.
  • Sikkes S; Department of Neurology, VU University Medical Center, Alzheimer Center, Amsterdam, The Netherlands; Department of Epidemiology and Biostatistics, VU University Medical Center, Alzheimer Center, Amsterdam, The Netherlands; Neuroscience Campus Amsterdam, VU University Medical Center, Alzheimer Center
  • Smart CM; Department of Psychology, University of Victoria, Victoria, BC, Canada; Institute on Aging and Lifelong Health, University of Victoria, Victoria, BC, Canada.
  • Snitz BE; Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA.
  • Sperling R; Center for Alzheimer Research and Treatment, Brigham and Women's Hosptial and Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • van der Flier WM; Department of Neurology, VU University Medical Center, Alzheimer Center, Amsterdam, The Netherlands; Department of Epidemiology and Biostatistics, VU University Medical Center, Alzheimer Center, Amsterdam, The Netherlands; Neuroscience Campus Amsterdam, VU University Medical Center, Alzheimer Center
  • Wagner M; Department of Psychiatry and Psychotherapy, University of Bonn, Bonn, Germany; German Center for Neurodegenerative Disorders (DZNE), Bonn-Cologne, Germany.
  • Jessen F; German Center for Neurodegenerative Disorders (DZNE), Bonn-Cologne, Germany; Department of Psychiatry, University Hospital Cologne, Medical Faculty, Cologne, Germany.
Alzheimers Dement ; 13(3): 296-311, 2017 Mar.
Article em En | MEDLINE | ID: mdl-27825022
ABSTRACT

INTRODUCTION:

Subjective cognitive decline (SCD) manifesting before clinical impairment could serve as a target population for early intervention trials in Alzheimer's disease (AD). A working group, the Subjective Cognitive Decline Initiative (SCD-I), published SCD research criteria in the context of preclinical AD. To successfully apply them, a number of issues regarding assessment and implementation of SCD needed to be addressed.

METHODS:

Members of the SCD-I met to identify and agree on topics relevant to SCD criteria operationalization in research settings. Initial ideas and recommendations were discussed with other SCD-I working group members and modified accordingly.

RESULTS:

Topics included SCD inclusion and exclusion criteria, together with the informant's role in defining SCD presence and the impact of demographic factors.

DISCUSSION:

Recommendations for the operationalization of SCD in differing research settings, with the aim of harmonization of SCD measurement across studies are proposed, to enhance comparability and generalizability across studies.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pesquisa Biomédica / Disfunção Cognitiva / Testes Neuropsicológicos Tipo de estudo: Guideline / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pesquisa Biomédica / Disfunção Cognitiva / Testes Neuropsicológicos Tipo de estudo: Guideline / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article